Positive attributes of anti-TERT CD4 T-Helper Type 1 immune responses in melanoma
Affiliation
Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, SpainIssue Date
2021
Metadata
Show full item recordAbstract
Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.Citation
Nagore E, Virós A, Kumar R. Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma [Internet]. Journal of Investigative Dermatology. Elsevier BV; 2021.Journal
Journal of Investigative DermatologyDOI
10.1016/j.jid.2021.09.005PubMed ID
34666894Additional Links
https://dx.doi.org/10.1016/j.jid.2021.09.005Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jid.2021.09.005
Scopus Count
Collections
Related articles
- Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
- Authors: Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O
- Issue date: 2022 Feb
- Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer.
- Authors: Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O
- Issue date: 2019 Aug
- Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4 + Th1 Response in Metastatic Non-Small Cell Lung Cancer.
- Authors: Wespiser M, Marguier A, Lecoester B, Richard T, Boullerot L, Malfroy M, Kumar A, Laheurte C, Adotévi O
- Issue date: 2023 Sep 1
- Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
- Authors: Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ
- Issue date: 2002 Sep 2
- Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
- Authors: Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O
- Issue date: 2012 Nov 15